| Identification | Back Directory | [Name]
Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- | [CAS]
2700035-54-5 | [Synonyms]
HDAC/HSP90-IN-3
Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- | [Molecular Formula]
C26H33N5O6 | [MOL File]
2700035-54-5.mol | [Molecular Weight]
511.57 |
| Hazard Information | Back Directory | [Uses]
HDAC/HSP90-IN-3 (compound J5) is a potent and selective fungal Hsp90 and HDAC dual inhibitor, with IC50 values of 0.83 and 0.91 μM, respectively. HDAC/HSP90-IN-3 shows antifungal activity against azole resistant C. albicans. HDAC/HSP90-IN-3 can suppress important virulence factors and down-regulate drug-resistant genes ERG11 and CDR1[1]. | [IC 50]
HSP90: 0.83 μM (IC50, fungal Hsp90); HDAC: 0.91 μM (IC50, fungal HDACs); human HDAC: 3.0 μM (IC50, human HDACs); HSP90: 19.52 μM (IC50, human Hsp90) | [References]
[1] Li C, Tu J, Han G, Liu N, Sheng C. Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans. Eur J Med Chem. 2022 Jan 5;227:113961. DOI:10.1016/j.ejmech.2021.113961 |
|
|